PMID- 25789534
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20161230
IS  - 1533-4058 (Electronic)
IS  - 1533-4058 (Linking)
VI  - 24
IP  - 3
DP  - 2016 Mar
TI  - Determination of True ERBB2 Gene Amplification in Breast Cancer by Quantitative 
      PCR Using a Reference and a Novel Control Gene.
PG  - 179-87
LID - 10.1097/PAI.0000000000000160 [doi]
AB  - Human epidermal growth factor receptor 2 (ERBB2/HER2) is amplified and 
      overexpressed in 20% to 25% of breast carcinomas, correlates with poor outcome, 
      and is an indication for treatment with trastuzumab. Accurate assessment of ERBB2 
      status is crucial for proper prognosis and to offer appropriate treatment for 
      patients. ERBB2 status is generally determined by immunohistochemistry or 
      fluorescence in situ hybridization (FISH), and sporadically by quantitative 
      real-time polymerase chain reaction (PCR). We developed a new algorithm, termed 
      quantitative PCR algorithm (QPA) score, and compared its performance with the 
      gold standard FISH assay. The QPA is a computation of the relative number of 
      copies of the ERBB2 gene with respect to a nonstandard, short-arm centromeric 
      sequence on chromosome 17, and referenced to a single-copy gene, RPP30. This 
      provides a more reliable determination of ERBB2 amplification, reducing the false 
      polysomy 17 error. A total of 69 breast carcinoma samples were tested for 
      quantitative real-time PCR and FISH, and the degree of concordance was analyzed. 
      Sixty-two cases were in agreement between the 2 methods, and the contingency 
      study assigned a kappa value of 0.729 for their correlation. A receiver operating 
      characteristic analysis was used to determine the optimal cut-off point for ERBB2 
      amplification, which was estimated at a QPA=1.53 (sensitivity=0.863; 
      specificity=0.944). Our data conclude that the QPA is able to determine ERBB2 
      gene status with high accuracy, while also overcoming the limitations of 
      conventional techniques and providing better cost-effectiveness.
FAU - Chamizo, Cristina
AU  - Chamizo C
AD  - Group of Cancer Biomarkers, Pathology Department, IIS-Fundacion Jimenez Diaz, 
      UAM, Madrid, Spain.
FAU - Rojo, Federico
AU  - Rojo F
FAU - Madoz-Gurpide, Juan
AU  - Madoz-Gurpide J
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Appl Immunohistochem Mol Morphol
JT  - Applied immunohistochemistry & molecular morphology : AIMM
JID - 100888796
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Breast Neoplasms/*genetics
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Real-Time Polymerase Chain Reaction/*methods
MH  - Receptor, ErbB-2/*genetics
EDAT- 2015/03/20 06:00
MHDA- 2016/12/15 06:00
CRDT- 2015/03/20 06:00
PHST- 2015/03/20 06:00 [entrez]
PHST- 2015/03/20 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
AID - 10.1097/PAI.0000000000000160 [doi]
PST - ppublish
SO  - Appl Immunohistochem Mol Morphol. 2016 Mar;24(3):179-87. doi: 
      10.1097/PAI.0000000000000160.